+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Dermatological Drugs Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941097

Global Dermatological Drugs Market Outlook

The global dermatological drugs market size was valued at USD 22.59 billion in 2023, driven by increasing shift towards biologics and targeted therapies across the globe. The market size is anticipated to grow at a CAGR of 11.3% during the forecast period of 2024-2032 to achieve a value of USD 59.2 billion by 2032.

Dermatological Drugs: Introduction

Dermatological drugs are medications specifically formulated to treat skin conditions and diseases. They encompass a wide range of products, including topical creams, ointments, gels, and systemic medications like oral pills and injectables. These drugs are used to treat various conditions such as acne, dermatitis, psoriasis, skin infections, and skin cancer. The choice of medication depends on the specific condition, its severity, and the patient's overall health, aiming to relieve symptoms, improve skin appearance, and prevent complications.

Key Trends in the Global Dermatological Drugs Market

There's a significant shift towards biologics and targeted therapies, particularly for chronic conditions like psoriasis and atopic dermatitis. These treatments focus on specific pathways or cells involved in the disease process, offering more efficacy and fewer side effects compared to traditional therapies.

Personalized or precision medicine approaches are becoming more prevalent, where treatments are tailored to individual patient characteristics, genetic makeup, or specific biomarkers.

Advances in formulation technology are improving the efficacy and patient compliance of topical treatments. Innovations include better drug delivery systems that enhance penetration of active ingredients and controlled-release mechanisms.

There's a growing market for cosmetic dermatological products, driven by an increasing emphasis on appearance and anti-aging. This includes treatments for wrinkles, pigmentation disorders, and hair loss.

Telemedicine and digital health apps are gaining traction for diagnosing and managing skin conditions. These technologies offer greater accessibility to dermatological care, particularly in underserved areas or during situations like the COVID-19 pandemic.

Research in regenerative medicine and stem cells is opening up new possibilities for treating skin conditions. This includes therapies for wound healing, scar reduction, and potentially even reversing hair loss.

The global increase in skin conditions, partly due to aging populations and environmental factors, is driving demand for dermatological treatments.

Despite the growth, companies in the dermatological drug market face challenges related to regulatory hurdles, pricing pressures, and reimbursement issues, impacting market dynamics and access to new treatments.

Global Dermatological Drugs Market Segmentation

Market Breakup by Diseases

  • Acne
  • Dermatitis
  • Psoriasis
  • Skin Cancer
  • Rosacea
  • Alopecia
  • Others

Market Breakup by Type

  • Prescription-based Drugs
  • Over-the-Counter Drugs

Market Breakup by Route of Administration

  • Topical Administration
  • Oral Administration
  • Parenteral Administration
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Dermatological Drugs Market Overview

In North America, the dermatological drugs market is advanced and dynamic, driven by a high focus on aesthetic appearance and quality of life. The region sees significant research and development activities, leading to the introduction of innovative treatments, including biologics for conditions like psoriasis and atopic dermatitis. Consumer awareness about skin health is high, fueling the demand for both prescription and over-the-counter skincare products. Regulatory support for rapid approval of breakthrough therapies also contributes to market dynamics.

Europe's market is characterized by stringent regulatory standards ensuring the safety and efficacy of dermatological drugs. There's a strong focus on research, with numerous initiatives aimed at understanding skin diseases at a molecular level and developing targeted treatments. Public healthcare systems in many European countries provide broad access to dermatological care, supporting market growth. The market is also influenced by a growing demand for cosmetic and anti-aging products alongside treatments for serious skin conditions.

The market in the Asia-Pacific region is rapidly expanding, driven by increasing consumer income, changing lifestyles, and a growing emphasis on personal appearance. The region has a high demand for skincare products, including those for acne, pigmentation disorders, and anti-aging. Cultural factors and climatic conditions also influence the prevalence of certain skin conditions, shaping market trends. However, the market is diverse, with variations in healthcare access and regulatory landscapes across different countries.

Global Dermatological Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • AbbVie Inc. (Allergan PLC)
  • Amgen Inc.
  • Galderma
  • GlaxoSmithKline Plc.
  • Leo Pharma
  • Johnson & Johnson
  • Novartis AG
  • Organon International (Merck & Co. Inc.)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Sanofi
  • Bausch Health Companies Inc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Dermatological Drugs Market Overview
3.1 Global Dermatological Drugs Market Historical Value (2017-2023)
3.2 Global Dermatological Drugs Market Forecast Value (2024-2032)
4 Global Dermatological Drugs Market Landscape
4.1 Global Dermatological Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Dermatological Drugs Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Dermatological Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Dermatological Drugs Market Segmentation
6.1 Global Dermatological Drugs Market by Diseases
6.1.1 Market Overview
6.1.2 Acne
6.1.3 Dermatitis
6.1.4 Psoriasis
6.1.5 Skin Cancer
6.1.6 Rosacea
6.1.7 Alopecia
6.1.8 Others
6.2 Global Dermatological Drugs Market by Type
6.2.1 Market Overview
6.2.2 Prescription-based Drugs
6.2.3 Over-the-Counter Drugs
6.3 Global Dermatological Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Topical Administration
6.3.3 Oral Administration
6.3.4 Parenteral Administration
6.3.5 Others
6.4 Global Dermatological Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.5 Global Dermatological Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Dermatological Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Dermatological Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Dermatological Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Dermatological Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Dermatological Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 AbbVie Inc. (Allergan PLC).
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Amgen Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Galderma
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 GlaxoSmithKline Plc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Leo Pharma
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Johnson & Johnson
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Organon International (Merck & Co. Inc.)
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Sun Pharmaceutical Industries Limited
17.10.1 Financial Analysis
17.10.1 Product Portfolio
17.10.2 Demographic Reach and Achievements
17.10.3 Mergers and Acquisition
17.10.4 Certifications
17.11 Sanofi
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Bausch Health Companies Inc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Bristol-Myers Squibb Company
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 F. Hoffmann-La Roche Ltd
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 AstraZeneca
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Dermatological Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • AbbVie Inc. (Allergan PLC).
  • Amgen Inc.
  • Galderma
  • GlaxoSmithKline Plc.
  • Leo Pharma
  • Johnson & Johnson
  • Novartis AG
  • Organon International (Merck & Co. Inc.)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Sanofi
  • Bausch Health Companies Inc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca

Methodology

Loading
LOADING...

Table Information